Open Access

Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination

  • Authors:
    • Takehiro Abiko
    • Takahiro Tsuchikawa
    • Kengo Miyauchi
    • Masataka Wada
    • Noriaki Kyogoku
    • Toshiaki Shichinohe
    • Yoshihiro Miyahara
    • Shinichi Kageyama
    • Hiroaki Ikeda
    • Hiroshi Shiku
    • Satoshi Hirano
  • View Affiliations

  • Published online on: January 10, 2018     https://doi.org/10.3892/ol.2018.7767
  • Pages: 3703-3711
  • Copyright: © Abiko et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Since 2009, a cancer vaccine clinical trial was conducted with melanoma antigen gene-A4 as an immunogenic agent. The levels of IgG1, IgG2 and IgG3, which are known to be Type 1 T helper cell‑associated antibodies, and the levels of IgG4 and IgE, which are known to be Type 2 T helper cell‑associated antibodies, were measured and used as biomarkers for predicting therapeutic effect. The results of the present study indicated a strong positive correlation between IgG2 and IgG4, with a correlation coefficient of R=0.808 (P<0.0001). The survival time of patients in which IgE responses were induced was significantly shorter compared with the survival time of patients with no IgE induction. The results of the present study suggest that caution is required when antigen‑specific IgE responses are induced during cancer vaccination therapy.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Abiko T, Tsuchikawa T, Miyauchi K, Wada M, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Shiku H, et al: Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncol Lett 15: 3703-3711, 2018
APA
Abiko, T., Tsuchikawa, T., Miyauchi, K., Wada, M., Kyogoku, N., Shichinohe, T. ... Hirano, S. (2018). Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncology Letters, 15, 3703-3711. https://doi.org/10.3892/ol.2018.7767
MLA
Abiko, T., Tsuchikawa, T., Miyauchi, K., Wada, M., Kyogoku, N., Shichinohe, T., Miyahara, Y., Kageyama, S., Ikeda, H., Shiku, H., Hirano, S."Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination". Oncology Letters 15.3 (2018): 3703-3711.
Chicago
Abiko, T., Tsuchikawa, T., Miyauchi, K., Wada, M., Kyogoku, N., Shichinohe, T., Miyahara, Y., Kageyama, S., Ikeda, H., Shiku, H., Hirano, S."Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination". Oncology Letters 15, no. 3 (2018): 3703-3711. https://doi.org/10.3892/ol.2018.7767